Lantheus Holdings, Inc. vs Amphastar Pharmaceuticals, Inc.: A Gross Profit Performance Breakdown

Pharma Giants' Gross Profit Surge: A Decade in Review

__timestampAmphastar Pharmaceuticals, Inc.Lantheus Holdings, Inc.
Wednesday, January 1, 201451256000125519000
Thursday, January 1, 201577347000135522000
Friday, January 1, 2016104189000137780000
Sunday, January 1, 201790795000162135000
Monday, January 1, 2018106985000174885000
Tuesday, January 1, 2019131923000174811000
Wednesday, January 1, 2020143340000138761000
Friday, January 1, 2021199739000187695000
Saturday, January 1, 2022248860000581703000
Sunday, January 1, 2023351121000709543000
Loading chart...

In pursuit of knowledge

A Decade of Gross Profit Growth: Lantheus Holdings vs. Amphastar Pharmaceuticals

In the competitive landscape of the pharmaceutical industry, Lantheus Holdings, Inc. and Amphastar Pharmaceuticals, Inc. have demonstrated remarkable growth in gross profit over the past decade. Since 2014, Lantheus Holdings has seen its gross profit soar by over 460%, reaching a peak in 2023. This impressive growth is highlighted by a significant jump in 2022, where profits nearly tripled compared to the previous year. Meanwhile, Amphastar Pharmaceuticals has also experienced a robust increase, with gross profit rising by approximately 585% during the same period. The year 2023 marked a milestone for Amphastar, as it achieved its highest gross profit to date. This data underscores the dynamic nature of the pharmaceutical sector and the strategic maneuvers these companies have employed to enhance their financial performance.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025